GreenPlan HRD
; Homologous Recombination Deficiency Test
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation
has opened up a new therapeutic avenue for high-grade ovarian cancers.
BRCA1 and BRCA2 proteins are essential for high-fidelity repair of double-strand breaks of DNA through the homologous recombination repair (HRR) pathway. Deficiency in HRR (HRD) is a target for PARP inhibitors.
The 50% of advanced ovarian cancer patient is HRD positive
Ovarian cancer has the worst prognosis of all gynecologic malignancies.
HRD tests in ovarian cancer is best assessed, not in terms of biological HRD status, but in terms of PARP inhibitor benefits.
Clinical trials evidence supports the use of BRCA mutation testing and two commercially available assays that also incorporate genomic instability for identifying subgroups of HGSCs.
Why is HRD test important?
It has proven that there is an advantage in the progressive-free survival,
when using targeted therapy (PRIMA, PAOLA-1) for HRD-positive patients with or without BRCA mutation.
According to the NCCN guidelines, the HRD status without g/BRCA 1/2 mutation may helpful to decide the PARP inhibitor therapy.
According to the ASCO guidelines, PARP inhibitor therapy is helpful to the epithelial ovarian cancer patients who meet all three of the following list. 1) Patients who relapsed within 6 months of platinum-based chemotherapy 2) Patients with g/sBRCA1/2 mutation or problems with Genomic instability 3) Patients without experience of PARP inhibitors
PARP inhibitors
Most notable anticancer drugs used in ovarian cancer suppress the activity of PARP protein, which is responsible for DNA repair process.
PARP inhibitors show unique effectiveness in tumors with HRD such as BRCA1/BRCA2 mutation.
GreenPlan HRD Test
▶ GreenPlan HRD test is conducted by NGS
HRD Test is conducted by Next Generation Sequencing (NGS)
Reporting GIS-score and sBRCA1/2 mutation result
▶ GreenPlan HRD test is calculating Genomic Instability Score(GIS).
Genomic Instability Score(GIS): Calculating with genomic scaes caused by HRD
GIS= LOH + TAI + LST
▶ GreenPlan HRD test provides a total of 28 HRD-related gene variants
including BRCA1 and BRCA2.
We identified and reported variants in 28 genes related to HRD.
The presence or absence of mutations in BRCA1 or BRCA2 affects HRD results, but the other 26 genes are reported regardless of HRD results.
Download the required documents through the link below!
This test can be performed upon request from a medical doctor.
#HRD #PARPinhibitor #Ovarian Cancer #GIS #Cancer #PrecisionOncology #SomaticMutation #CancerTherapy #Immunotherapy #TargetTherapy